Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-24-000183
Filing Date
2024-11-13
Accepted
2024-11-13 17:44:50
Documents
3
Period of Report
2024-11-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1731537882.html 3  
1 FORM 3 wk-form3_1731537882.xml 3 1676
2 EX-24 section16poaforworkiva.htm EX-24 3913
3 GRAPHIC section16poaforworkiva001.jpg GRAPHIC 242641
  Complete submission text file 0001725160-24-000183.txt   341595
Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
Myers Scott Dunseth (Reporting) CIK: 0001356256 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 241455932

Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)